EndoBarrier® maker, GI Dynamics, Inc. is trumpeting five prestigious new centres in Europe that have begun offering its therapy. In addition to three new centres in Germany, a country where EndoBarrier Therapy became available in late 2011, GI Dynamics has expanded its commercial presence into Spain and Switzerland.
Background
EndoBarrier Therapy is a revolutionary, non-surgical, non-pharmaceutical treatment proven to help people living with uncontrolled type 2 diabetes and obesity achieve rapid and dramatic reductions in blood sugar levels, as well as substantial weight loss. We’ve covered it extensively thus far, most recently earlier this year when it was launched in Israel.
The new centres offering treatment with EndoBarrier Therapy are:
Hospital Universitari De Bellvitge, Barcelona, Spain
Universitätsspital Zürich, Zurich, Switzerland
Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern, Munich, Germany
Klinikum Bogenhausen – Klinikum München GmbH, Munich, Germany
St. Martinus-Krankenhaus Düsseldorf in collaboration with the Deutsches Diabetes-Zentrum Düsseldorf, Düsseldorf, Germany
Company comments
“We are continuing to invest in supporting the expansion of EndoBarrier Therapy in the European Union, an important region of the world where reimbursement is critical to long-term sales growth,” said Mark C. Twyman, chief commercial officer of GI Dynamics. “As we continue to build the case for expanded reimbursement in Germany and local reimbursement in other countries, we are pleased to be working with these new centres, which are among the most prestigious institutions in their respective countries. In addition to expanding our commercial footprint in Europe, we continue to make important progress in self-pay markets and look forward to sharing updates on these efforts in the near future.”
Source: G I Dynamics, Inc.
published: June 20, 2013 in: Gastroenterology, Healthcare, News